Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease
Juan Pablo Arab, Marco Arrese, Michael Trauner
Annual Review of Pathology Mechanisms of Disease (2018) Vol. 13, Iss. 1, pp. 321-350
Open Access | Times Cited: 476

Showing 1-25 of 476 citing articles:

Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease
Ze Chen, Ruifeng Tian, Zhi‐Gang She, et al.
Free Radical Biology and Medicine (2020) Vol. 152, pp. 116-141
Open Access | Times Cited: 899
The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)
Daniela Maria Tănase, Evelina Maria Gosav, Claudia Florida Costea, et al.
Journal of Diabetes Research (2020) Vol. 2020, pp. 1-16
Open Access | Times Cited: 392
Arachidonic Acid Metabolites in Cardiovascular and Metabolic Diseases
Thomas Sonnweber, Alex Pizzini, Manfred Nairz, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 11, pp. 3285-3285
Open Access | Times Cited: 351
Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity
Herbert Tilg, Timon E. Adolph, Michael Dudek, et al.
Nature Metabolism (2021) Vol. 3, Iss. 12, pp. 1596-1607
Closed Access | Times Cited: 287
Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits
Moritz Peiseler, Robert F. Schwabe, Jochen Hampe, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1136-1160
Open Access | Times Cited: 287
Hesperetin ameliorates hepatic oxidative stress and inflammationviathe PI3K/AKT-Nrf2-ARE pathway in oleic acid-induced HepG2 cells and a rat model of high-fat diet-induced NAFLD
Jingda Li, Tianqi Wang, Panpan Liu, et al.
Food & Function (2021) Vol. 12, Iss. 9, pp. 3898-3918
Closed Access | Times Cited: 268
How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?
Yana Geng, Klaas Nico Faber, Vincent E. de Meijer, et al.
Hepatology International (2021) Vol. 15, Iss. 1, pp. 21-35
Open Access | Times Cited: 244
Chronic tissue inflammation and metabolic disease
Yun Sok Lee, Jerrold M. Olefsky
Genes & Development (2021) Vol. 35, Iss. 5-6, pp. 307-328
Open Access | Times Cited: 192
Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?
Judith Aron‐Wisnewsky, Moritz V. Warmbrunn, Max Nieuwdorp, et al.
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1881-1898
Open Access | Times Cited: 180
Role of the Inflammasome in Liver Disease
Marcelle de Carvalho Ribeiro, Gyöngyi Szabó
Annual Review of Pathology Mechanisms of Disease (2021) Vol. 17, Iss. 1, pp. 345-365
Open Access | Times Cited: 176
Animal models of NAFLD from a hepatologist's point of view
Daniel Jahn, Stefan Kircher, Heike M. Hermanns, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2018) Vol. 1865, Iss. 5, pp. 943-953
Open Access | Times Cited: 169
Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
Simona Marchisello, Antonino Di Pino, Roberto Scicali, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 8, pp. 1948-1948
Open Access | Times Cited: 169
Pathophysiology of obesity and its associated diseases
Xin Jin, Tingting Qiu, Li Li, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2403-2424
Open Access | Times Cited: 165
Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease
Evangelia Makri, A. Goulas, Stergios A. Pοlyzos
Archives of Medical Research (2020) Vol. 52, Iss. 1, pp. 25-37
Closed Access | Times Cited: 163
FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome
Fuming Li, Peiwei Huangyang, Michelle Burrows, et al.
Nature Cell Biology (2020) Vol. 22, Iss. 6, pp. 728-739
Open Access | Times Cited: 149
Novel therapeutic targets for cholestatic and fatty liver disease
Michael Trauner, Claudia Fuchs
Gut (2021) Vol. 71, Iss. 1, pp. 194-209
Open Access | Times Cited: 129
Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development
Xiaochen Wang, Qifeng He, Chuanli Zhou, et al.
Immunity (2022) Vol. 56, Iss. 1, pp. 58-77.e11
Open Access | Times Cited: 110
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 764-783
Closed Access | Times Cited: 90
IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease
Jiwoon Park, Yuanyuan Zhao, Fan Zhang, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 1, pp. 45-56
Open Access | Times Cited: 77
Clinical Trial Landscape in NASH
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 21, Iss. 8, pp. 2001-2014
Closed Access | Times Cited: 74
Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Tobias Puengel, Hanyang Liu, Adrien Guillot, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 5, pp. 2668-2668
Open Access | Times Cited: 73
Lifestyle changes in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis
Tiziana Fernández, Macarena Viñuela, Catalina Vidal, et al.
PLoS ONE (2022) Vol. 17, Iss. 2, pp. e0263931-e0263931
Open Access | Times Cited: 69
Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease
Ruxin Gao, Yue Li, Zhimeng Xu, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1800-1815
Closed Access | Times Cited: 69
Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice
Qian Ye, Yi Liu, Guiji Zhang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 68
Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis
Menooa Ebrahimi, Seyed Arsalan Seyedi, Seyed Ali Nabipoorashrafi, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top